Patents by Inventor Lewis J. Gazzard
Lewis J. Gazzard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11963994Abstract: Novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies and have the general formula I: wherein R1, R2, R3, R4, R5 and R6 are as described herein.Type: GrantFiled: August 3, 2021Date of Patent: April 23, 2024Assignee: Genentech, Inc.Inventors: Frederick Cohen, Lewis J. Gazzard, Vickie Hsiao-Wei Tsui, John A. Flygare
-
Patent number: 11612606Abstract: 3-Carbonylamino-8-aminoisoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the 3-carbonylamino-8-aminoisoquinoline compounds.Type: GrantFiled: October 3, 2019Date of Patent: March 28, 2023Assignee: Genentech, Inc.Inventors: Jun Liang, Rohan V. Mendonca, Michael Siu, John Tellis, Weiru Wang, BinQing Wei, Bryan Chan, Edna F. Choo, Joy Drobnick, Lewis J. Gazzard, Timothy Heffron
-
Publication number: 20220281893Abstract: Provided herein are tetracyclic oxazepinyl compounds useful in the treatment on cancers.Type: ApplicationFiled: February 7, 2022Publication date: September 8, 2022Applicant: Genentech, Inc.Inventors: Lewis J. GAZZARD, Samantha Alyson GREEN, Matthew Leo LANDRY, Sushant MALHOTRA, Michael SIU, Steven DO, Yun-Xing CHENG, Limin CHENG, Jianfeng XIN, Mingtao HE
-
Publication number: 20220211797Abstract: Novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies and have the general formula I: wherein R1, R2, R3, R4, R5 and R6 are as described herein.Type: ApplicationFiled: August 3, 2021Publication date: July 7, 2022Applicant: GENENTECH, INC.Inventors: Frederick COHEN, Lewis J. GAZZARD, Vickie Hsiao-Wei TSUI, John A. FLYGARE
-
Publication number: 20220073520Abstract: Cinnoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the cinnoline compounds.Type: ApplicationFiled: March 26, 2021Publication date: March 10, 2022Applicant: Genentech, Inc.Inventors: Sushant Malhotra, Michael Siu, Weiru Wang, BinQing Wei, Aihe Zhou, Bryan K. Chan, Lewis J. Gazzard, Timothy Heffron, Michael Lainchbury, Andrew Madin, Eileen Mary Seward, Matthew W. Cartwright, Emanuela Gancia, David Favor, Kin Chiu Fong, Andrew Good, Yonghan Hu
-
Patent number: 11242344Abstract: The present disclosure relates to bifunctional compounds, which can be used as modulators of targeted ubiquitination. In particular, the present disclosure is directed to compounds which contain on one end a VHL ligand moiety, which binds to the VHL E3 ubiquitin ligase, and on the other end a moiety that binds a target protein such that degradation of the target protein/polypeptide is effectuated. Also disclosed are VHL ligands.Type: GrantFiled: April 24, 2020Date of Patent: February 8, 2022Assignee: Genentech, Inc.Inventors: Nicole Blaquiere, Peter Dragovich, Lewis J. Gazzard, Thomas Pillow, Steven T. Staben, Binqing Wei, Jianfeng Xin
-
Publication number: 20210332064Abstract: 3-Carbonylaminoisoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the 3-carbonylaminoisoquinoline compounds.Type: ApplicationFiled: April 1, 2021Publication date: October 28, 2021Applicant: Genentech, Inc.Inventors: Jun Liang, Rohan V. Mendonca, Michael Siu, John Tellis, Weiru Wang, BinQing Wei, Bryan Chan, Edna F. Choo, Joy Drobnick, Lewis J. Gazzard, Timothy Heffron
-
Publication number: 20210309660Abstract: The present disclosure relates to bifunctional compounds, which can be used as modulators of targeted ubiquitination. In particular, the present disclosure is directed to compounds which contain on one end a VHL ligand moiety, which binds to the VHL E3 ubiquitin ligase, and on the other end a moiety that binds a target protein such that degradation of the target protein/polypeptide is effectuated. Also disclosed are VHL ligands.Type: ApplicationFiled: April 24, 2020Publication date: October 7, 2021Inventors: Nicole Blaquiere, Peter Dragovich, Lewis J. Gazzard, Thomas Pillow, Steven T. Staben, Binqing Wei, Jianfeng Xin
-
Publication number: 20210277024Abstract: Naphthyridine compounds of formula (I). variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.Type: ApplicationFiled: January 22, 2021Publication date: September 9, 2021Applicant: Genentech, Inc.Inventors: Terry Kellar, Jun Liang, Sushant Malhotra, Rohan V. Mendonca, Michael Siu, Craig Stivala, John C. Tellis, BinQing Wei, Bryan K. Chan, Lewis J. Gazzard, Timothy Heffron, Graham Jones, Michael Lainchbury, Andrew Madin, Eileen Mary Seward, Matthew W. Cartwright, Emanuela Gancia, David Favor, Kin Chiu Fong, Andrew Good, Yonghan Hu
-
Patent number: 11096982Abstract: Novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies and have the general formula I: wherein R1, R2, R3, R4, R5 and R6 are as described herein.Type: GrantFiled: April 2, 2019Date of Patent: August 24, 2021Assignee: GENENTECH, INC.Inventors: Frederick Cohen, Lewis J. Gazzard, Vickie Hsiao-Wei Tsui, John A. Flygare
-
Publication number: 20210253580Abstract: Isoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.Type: ApplicationFiled: January 22, 2021Publication date: August 19, 2021Applicant: Genentech, Inc.Inventors: Jun Liang, Sushant Malhotra, Rohan V. Mendonca, Naomi Rajapaksa, Michael Siu, Craig Stivala, John C. Tellis, BinQing Wei, Bryan K. Chan, Joy Alison Drobnick, Lewis J. Gazzard, Timothy Heffron, Graham Jones, Michael Lainchbury, Andrew Madin, Eileen Mary Seward, Matthew W. Cartwright, Emanuela Gancia, David Favor, Kin Chiu Fong, Andrew Good, Yonghan Hu
-
Publication number: 20210221821Abstract: The present disclosure relates to compounds and salts thereof that are useful for inhibiting target polypeptides and proteins, in particular, bromodomain (e.g., BRD4) proteins. Also disclosed are pharmaceutical compositions comprising the compounds, or a salt (e.g., a pharmaceutically acceptable salt) thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated diseases or disorders.Type: ApplicationFiled: March 10, 2021Publication date: July 22, 2021Applicant: Genentech, Inc.Inventors: Robert Anthony BLAKE, Peter DRAGOVICH, Lewis J. GAZZARD, Susan KAUFMAN, Tracy KLEINHEINZ, Thomas PILLOW, Steven T. STABEN, Binqing WEI
-
Publication number: 20200108075Abstract: 3-Carbonylamino-8-aminoisoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the 3-carbonylamino-8-aminoisoquinoline compounds.Type: ApplicationFiled: October 3, 2019Publication date: April 9, 2020Applicant: Genentech, Inc.Inventors: Jun LIANG, Rohan V. MENDONCA, Michael SIU, John TELLIS, Weiru WANG, BinQing WEI, Bryan CHAN, Edna F. CHOO, Joy DROBNICK, Lewis J. GAZZARD, Timothy HEFFRON
-
Publication number: 20190224269Abstract: Novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies and have the general formula I: wherein R1,R2,R3,R4,R5 and R6 are as described herein.Type: ApplicationFiled: April 2, 2019Publication date: July 25, 2019Applicant: GENENTECH, INC.Inventors: Frederick Cohen, Lewis J. Gazzard, Vickie Hsiao-Wei Tsui, John A. Flygare
-
Publication number: 20170136084Abstract: Novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies and have the general formula I: wherein R1, R2, R3, R4, R5 and R6 are as described herein.Type: ApplicationFiled: January 31, 2017Publication date: May 18, 2017Applicant: GENENTECH, INC.Inventors: Frederick COHEN, Lewis J. GAZZARD, Vickie Hsiao-Wei TSUI, John A. FLYGARE
-
Patent number: 9586991Abstract: Novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies and have the general formula I: wherein R1, R2, R3, R4, R5 and R6 are as described herein.Type: GrantFiled: December 18, 2015Date of Patent: March 7, 2017Assignee: GENENTECH, INC.Inventors: Frederick Cohen, Lewis J. Gazzard, Vickie Hsiao-Wei Tsui, John A. Flygare
-
Publication number: 20160102119Abstract: Novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies and have the general formula I: wherein R1, R2, R3, R4, R5 and R6 are as described herein.Type: ApplicationFiled: December 18, 2015Publication date: April 14, 2016Applicant: GENENTECH, INC.Inventors: Frederick COHEN, Lewis J. GAZZARD, Vickie Hsiao-Wei TSUI, John A. FLYGARE
-
Publication number: 20160060262Abstract: The invention provides novel compounds having the general formula: wherein X1 is N or N+O?, and one of X2, X3 and X4 is N or N+—O? and the remainder of X2, X3 and X4 is C. R2, R3, R4, R5, R6. A, B and Y are as described herein. Additionally compositions compounds of Formula I and methods of use are further described herein.Type: ApplicationFiled: October 30, 2015Publication date: March 3, 2016Applicant: GENENTECH, INC.Inventors: Joseph P. Lyssikatos, Lewis J. Gazzard, Emily Hanan, Samuel S. Kintz, Hans Edward Purkey
-
Patent number: 9238675Abstract: Novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies and have the general formula I: wherein R1, R2, R3, R4, R5 and R6 are as described herein.Type: GrantFiled: May 5, 2014Date of Patent: January 19, 2016Assignee: GENENTECH, INC.Inventors: Frederick Cohen, Lewis J. Gazzard, Vickie Hsiao-Wei Tsui, John A. Flygare
-
Publication number: 20150368244Abstract: The invention relates to 1,5-diazacarbazole compounds of Formula (I), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g) and (I-h) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.Type: ApplicationFiled: December 20, 2013Publication date: December 24, 2015Applicant: Genentech, Inc.Inventors: Hazel Joan Dyke, Emanuela Gancia, Lewis J. Gazzard, Simon Charles Goodacre, Joseph P. Lyssikatos, Calum MacLeod, Karen Williams, Huifen Chen